[PP.35.06]

• DOI: 10.1097/01.hjh.0000468802.03579.13
• Publication Date: 2015-06-23T18:35:58Z
• Authors: T. Konoshita; T. Nakaya; I. Sakai; K. Yamamoto; M. Yamada; M. Ichikawa; S. Sato; M. Imagawa; Y. Makino; M. Fujii; Y. Zenimaru; J. Suzuki; T. Ishizuka
• Keywords: Amlodipine; Calcium channel blocker; Plasma renin activity; N-type calcium channel

Objective: Calcium channel blocker (CCB) is one of the most useful anti-hypertensive agents without severe adverse effects. However, activation renin-angiotensin system (RAS) unfavorable characteristics CCB in a stand point organ protection. N type calcium thought to be involved renin release via sympathetic and aldosterone from adrenal cortex. Accordingly, N/L has probability less elevation concentrations among CCBs. The objective study compare circulatory RAS levels (plasma activity (PRA), plasma concentration (PAC)) anti-albuminuric effect between L blocker, amlodipine, cilnidipine, on top an ARB, valsartan. Design method: Subjects were 68 hypertensives administered with valsartan (male/female 37/31, age 66.9 ± 10.5yrs, SBP/DBP 145.1 15.6/86.3 10.1 mmHg, s-Cr 0.78 0.30 mg/dl, PRA1.6 2.1 ng/ml/hr, PAC 63.5 32.0 pg/ml, urinary albumin excretion (UAE) 119.9 201.3 mg/gCr). Daily 5–10 mg amlodipine or 10–20 cilnidipine for 12 weeks cross-over manner data taken before after each drug administration. differences analyzed by paired t-test signed rank test. Results: Results as follows (valsartan + vs. cilnidipine): (mmHg): 131.6 10.2/75.9 9.6 131.1 9.8/75.8 10.0, p = 0.74/0.95, PRA (ng/ml/hr): 2.9 3.3 3.9 5.8 0.15, (pg/ml): 76.2 30.3 24.2, < 0.05, UAE (mg/gCr): 105.5 220.2 69.5 115.5, 0.05. Thus, spite comparable BP reductions, at administration was significantly lower than those Besides, that Conclusions: In conclusion, it suggested leads compared might superior